Your institution may have access to this item. Find your institution then sign in to continue.
Title
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
Authors
Chi, K N; Ellard, S L; Hotte, S J; Czaykowski, P; Moore, M; Ruether, J D; Schell, A J; Taylor, S; Hansen, C; Gauthier, I; Walsh, W; Seymour, L
Abstract
The purpose of this trial was to evaluate the antitumor activity of sorafenib, a multikinase inhibitor of cell proliferation and angiogenesis, in patients with castration-resistant prostate cancer.
Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Vol 19, Issue 4, p746